What's new

Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Date of authorisation: 04/04/2022, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Date of authorisation: 04/04/2022, Revision: 9, Status: Authorised

May 7, 2025 - 15:09
 0
Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Date of authorisation: 04/04/2022, Revision: 9, Status: Authorised
Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Date of authorisation: 04/04/2022, Revision: 9, Status: Authorised
Read More

Tags:

Previous Article

Xellia to shutter Copenhagen antibiotics plant, dealing a blow to EU reshoring e...

Next Article

JinkoSolar, LONGi, JA Solar, and Trina Solar ship 65GW modules in Q1 2025, all r...

Related Posts

Business process description for marketing authorisatio...

Apr 22, 2025  0

Human medicines European public assessment report (EPAR): Spedra, avanafil, Date of authorisation: 21/06/2013, Date of refusal: 26/04/2013, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 28, 2025  0

Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine, Date of authorisation: 06/01/2021, Revision: 54, Status: Authorised

Human medicines European public assessment report (EPAR...

May 5, 2025  0